Dr Meg Spriggs completed her PhD in psychology at the University of Auckland, New Zealand, where she investigated the application of electrophysiological (EEG) markers of neuroplasticity in understanding brain health and disease. Following this, she moved to the Centre for Psychedelic Research at Imperial College London, where she has been developing and leading the first study of psilocybin assisted therapy for anorexia nervosa in the UK and Europe; a study which commenced in May 2021. Alongside this, Meg has worked as co-ordinator and guide on other ongoing psilocybin trials, has continued to develop electrophysiological measures of neuroplasticity for use in psychedelic research, and has been engaging in projects exploring equitable, accessible and ethical approaches to psychedelics.